Canadian researchers gave more than 5,500 people with heart disease or diabetes either a daily placebo or a combination of folic acid (2,500 mcg), vitamin B-6 (50 mg), and vitamin B-12 (1,000 mcg) as part of the Heart Outcomes Prevention Evaluation (HOPE-2) trial.
What does HOPE stand for?
HOPE stands for Heart Outcomes Prevention Evaluation
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of HOPE
We have 233 other meanings of HOPE in our Acronym Attic
- Healing Our Personal Environment
- Healing, Opportunity, Prevention, Education (domestic violence awareness; Tacoma, WA)
- Health Opportunities for People Everywhere
- Health Opportunities through Physical Education
- Health Options & Positive Energy Foundation
- Health Organization to Preserve the Environment
- Health Outcomes and Pharmacoeconomic (Research Centre)
- Hearing Other People's Experiences (Alcoholic Anonymous)
- Heart of the Ozarks Parent Educators
- Heart Open Please Enter (Alcoholics Anonymous)
- Hell on Planet Earth
- Help Our People Excel
- Helping Obese People through Education
- Helping Online People Everywhere (song project)
- Helping Open People's Eyes, Inc. (Texas; est. 1990)
- Helping Other Patients Everywhere
- Helping Other People Eat
- Helping Other People Enthusiastically (outreach program; various locations)
- Helping Other People Everyday
- Helping Other People Excel
Samples in periodicals archive:
The Heart Outcomes Prevention Evaluation (HOPE) study found that ramipril (Altace), an ACE inhibitor, seemed to be beneficial in advanced CKD (N.
led the Heart Outcomes Prevention Evaluation (HOPE) study, which produced the finding.
Because the persuasive bulk of the randomized clinical trial data, including the nearly 10,000-patient Heart Outcomes Prevention Evaluation (HOPE) trial as well as the 12,218-patient European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease (EUROPA), has shown that ACE inhibitor therapy results in a highly significant 20%-22% reduction in atherosclerotic events in patients with CAD or other vascular disease but no history of heart failure or depressed left ventricular systolic function.